Ozempic’s $274 Medicare price in 2027: what will you actually pay?

What is Ozempic’s $274 Medicare price, and who pays it?

It is Medicare’s negotiated price for a 30-day supply of Ozempic, Rybelsus or Wegovy from January 1, 2027, and it isn’t your copay.^1,8

The law calls it the “maximum fair price”. CMS, which runs Medicare, set it with the maker under the Medicare Drug Price Negotiation Program.¹ The 2024 list price was $959, so the cut is 71%.¹

Semaglutide is the medicine; Ozempic, Rybelsus and Wegovy are brands of it, approved for different uses.^11,12 Think of acetaminophen: it is the medicine, and Tylenol is a brand name on the box.

The maker must make the price available to the pharmacies that fill your prescription. Part D plans must put the drugs on their drug lists.¹ Your own share still runs through your plan’s deductible and copays, explained below.

• Scale: 2,282,000 people with Part D used one of the three brands in 2024, at about $15.2 billion in total costs.¹
• Savings estimate: CMS expects the 15 new 2027 prices to save Part D members about $685 million out of pocket.¹
• After 2027: the price rises each year with inflation, measured by the consumer price index.¹

Why won’t a box of Wegovy cost $274?

Because CMS sets a price for each pack, and a box of four Wegovy pens works out at about $386, not $274.^1,3

Every Wegovy pen box has the same price, from the starting dose to 7.2 mg.³ Ozempic tablets and the Wegovy pill were added to CMS’s list in 2026.³

Separately, Novo Nordisk is cutting its list price for Wegovy 2.4 mg injection and 25 mg tablets, Ozempic 0.5, 1 and 2 mg, and Rybelsus 7 and 14 mg to $675 a month.⁶ The cut starts on January 1, 2027.⁶ Medicare’s negotiated prices sit below that.

What will you pay for Ozempic in 2027, phase by phase?

You pay the plan’s full price until your deductible is met, then a copay or coinsurance, and nothing once your costs reach $2,400.^5,7

• The deductible: at most $700 in 2027. In Medicare’s standard design you pay 100% of the drug’s price here; some plans have a lower deductible or none.^7,5
• After the deductible: the standard design charges 25% for negotiated drugs. Plans can use other designs.⁷ A copay is a fixed amount; coinsurance is a percentage.⁵
• After the cap: once you’ve paid $2,400 for covered drugs, you pay $0 for the rest of the year.^5,9

The lower price shows up most where your share is tied to the price: the deductible and coinsurance. A fixed copay is set by the plan, so it may not drop.⁵

We checked one drug plan in Medicare’s Plan Finder for both years. In 2026, a 2 mg Ozempic pen cost $1,004.89 before the deductible and $251.22 after it. In 2027, it is $277.29 and $69.32.⁹

Over 12 monthly fills that comes to $2,100 in 2026 and about $1,357 in 2027, by our arithmetic.⁹ It’s one plan, one dose and one pharmacy, so treat it as an example.

Other drugs can still take you to the $2,400 cap. People with Extra Help pay at most $12.65 a fill for brand-name drugs in 2026 and $14.40 in 2027.⁷ So their bill changes less.

Does the negotiated price help if you take Wegovy for your heart?

Yes, if your plan approves it: Part D can cover Wegovy to lower heart risk, at a negotiated price of about $386 a box.^2,3

KFF says Part D plans can cover GLP‑1s for uses other than obesity, including lowering heart risk.² Wegovy is approved to cut the risk of heart attack, stroke and heart death in adults with heart disease and obesity or overweight.¹²

In 2026, the plan we checked didn’t list Wegovy. In 2027, both plans we opened listed it, with prior authorization and a quantity limit.⁹ That fits CMS’s rule that plans must list negotiated drugs.¹

The 2027 estimate was $386.13 before the deductible and $96.53 after it, about $1,683 over 12 fills by our arithmetic.⁹ More on these uses is in Wegovy for heart and liver. People with MASH, a fatty liver disease, can’t use the Bridge; Medicare says their plan may already cover a GLP‑1.¹⁰

What doesn’t change in 2027?

Weight-loss-only use is still excluded from Part D, the $50 Bridge still runs separately, and Zepbound and Mounjaro have no negotiated price.^14,10,1

• Weight alone: Part D excludes weight-loss drugs “even if used for a non-cosmetic purpose”.¹⁴ Being on a plan’s drug list doesn’t change that.²
• The Bridge: $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, for people who meet its criteria, through December 31, 2027.^10,2 It sits outside Part D and doesn’t count toward the cap.¹⁰ For Bridge drugs, KFF reports the makers agreed a separate net price of $245 a month. That deal doesn’t change the $274 Part D price or your $50 copay.² See the Bridge explained.
• After the Bridge: CMS said it won’t start its longer-term model (BALANCE) in Medicare in 2027. KFF says it is uncertain how people will keep coverage after 2027.²
• Tirzepatide: Mounjaro and Zepbound aren’t among the 15 drugs with 2027 negotiated prices.¹
• Savings cards: the makers’ cards still exclude Medicare. See does the savings card work with Medicare?

What should you check before December 7?

Check your plan’s 2027 tier, prior authorization and price for your exact pack, then compare plans in Medicare’s Plan Finder before open enrollment closes.⁹

Open enrollment runs October 15 to December 7, 2026. Our step-by-step guide is how to check a Part D plan for Ozempic, Wegovy or Zepbound. The full set of rules is in how Medicare covers GLP‑1 medicines. Prices and prescriptions are in our prescriptions guide.

Questions people ask

How we researched this

More from the US blog

USUnited StatesMedicare open enrollment 2026: how do you check a Part D plan covers Ozempic, Wegovy or Zepbound?USUnited StatesDoes Medicare cover Wegovy or Zepbound? The $50 Medicare GLP‑1 Bridge explainedUSUnited StatesIs Wegovy covered for heart protection or fatty liver (MASH) when weight loss isn’t?